Climb Bio (CLYM)
NASDAQ:CLYM
CLYM Stock Chart & Stats
$7.11
-$0.15(-7.18%)
At close: 4:00 PM EST
$7.11
-$0.15(-7.18%)
Day’s Range― - ―
52-Week Range$1.05 - $8.04
Previous CloseN/A
Volume51.97K
Average Volume (3M)586.39K
Market Cap
$339.63M
Enterprise Value$449.65M
Total Cash (Recent Filing)$101.08M
Total Debt (Recent Filing)$541.00K
Price to Earnings (P/E)―
Beta1.26
Next Earnings
May 19, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding47,767,980
10 Day Avg. Volume478,370
30 Day Avg. Volume586,386
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-4.97
Enterprise Value/Market Cap1.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.61K
Enterprise Value/Ebitda-7.05
Forecast
1Y Price Target
$16.67Price Target Upside134.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.12
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Engineered Antibody DesignCLYM116's sweeper mechanism combined with an engineered Fc may prolong exposure while promoting APRIL breakdown and reducing large immune complexes, potentially improving dosing convenience and lowering immunogenicity.
Pipeline Breadth Across IndicationsA diversified pipeline with lead programs targeting APRIL and CD19 across primary membranous nephropathy, immune thrombocytopenic purpura, IgA nephropathy, and systemic lupus erythematosus offers multiple independent opportunities for value-driving clinical readouts.
Unmet Medical Need In Primary Membranous NephropathyPrimary membranous nephropathy lacks approved treatments, so a successful budoprutug program could meet a significant unmet need and create meaningful commercial upside.
Bears Say
Mid-stage Clinical UncertaintyClinical success for budoprutug remains unproven and is contingent on mid-stage trial outcomes, creating execution risk that could delay or limit program progress.
Profitability ConcernsA substantially negative return on equity indicates persistent profitability challenges that could weigh on investor confidence and the company’s valuation.
Regulatory And Commercial Execution RiskDevelopment programs face material regulatory and commercial risks that could complicate approval pathways or reduce market uptake, negatively affecting long-term prospects.
Climb Bio News
CLYM FAQ
What was Climb Bio’s price range in the past 12 months?
Climb Bio lowest stock price was $1.05 and its highest was $8.04 in the past 12 months.
What is Climb Bio’s market cap?
Climb Bio’s market cap is $339.63M.
When is Climb Bio’s upcoming earnings report date?
Climb Bio’s upcoming earnings report date is May 19, 2026 which is in 53 days.
How were Climb Bio’s earnings last quarter?
Climb Bio released its earnings results on Mar 05, 2026. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.197 by -$0.063.
Is Climb Bio overvalued?
According to Wall Street analysts Climb Bio’s price is currently Undervalued.
Does Climb Bio pay dividends?
Climb Bio does not currently pay dividends.
What is Climb Bio’s EPS estimate?
Climb Bio’s EPS estimate is -0.29.
How many shares outstanding does Climb Bio have?
Climb Bio has 47,767,980 shares outstanding.
What happened to Climb Bio’s price movement after its last earnings report?
Climb Bio reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.197. Following the earnings report the stock price went up 1.511%.
Which hedge fund is a major shareholder of Climb Bio?
Currently, no hedge funds are holding shares in CLYM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Climb Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.67 (134.46% Upside)
$16.67 (134.46% Upside)
Blogger Sentiment
Bullish
CLYM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 19.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $24.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
436.92%
12-Months-Change
Fundamentals
Return on Equity
-33.41%
Trailing 12-Months
Asset Growth
-22.77%
Trailing 12-Months
Company Description
Climb Bio
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
CLYM Stock 12 Month Forecast
Average Price Target
$16.67
▲(134.46% Upside)
Technical Analysis
Agenus
―
TuHURA Biosciences
―
Ovid Therapeutics
―
Cognition Therapeutics
―
Tevogen Bio Holdings
―
Ownership Overview
24.12% Insiders
6.45% Mutual Funds
47.19% Other Institutional Investors
19.66% Public Companies and
Individual Investors